Profiles of Medicaid Beneficiaries with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray.

ABSTRACT:

Introduction

While the literature on esketamine use in commercially insured patients with treatment-resistant depression (TRD) is growing, data on Medicaid beneficiaries remain limited. This study aimed to fill this gap by exploring characteristics of Medicaid beneficiaries with TRD who initiated esketamine treatment in the United States.

Methods

Adults with TRD initiating esketamine on/after 03/05/2019 (index date) were selected from the Merative™ MarketScan^® Multi-State Medicaid Database (01/2016-06/2022). Baseline was 12 months pre-index date; follow-up spanned from the index date until the end of health plan insurance or data. Patient baseline characteristics and follow-up treatment patterns, healthcare resource utilization (HRU), and medical costs were report

SUBMITTER: Clemens K 

PROVIDER: S-EPMC12450134 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature